Stocks Health care RGC

NASDAQ · Health care

Regencell Bioscience Holdings Ltd (RGC)

It posted a net loss of $11.7M. At June 30, 2026 it held $14.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on October 7, 2026.

Watch RGC in 60 seconds

Follow RGC

Free, no password. An email when RGC files with the SEC.

Key facts about Regencell Bioscience Holdings Ltd

Net worth

Regencell Bioscience Holdings Ltd has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $13.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2026 operations used $7.7M of cash.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on October 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Regencell Bioscience Holdings Ltd's next report is expected around September 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Regencell Bioscience Holdings Ltd does

Regencell Bioscience Holdings Ltd is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker RGC.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Regencell Bioscience Holdings Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 7, 2026
   Annual report (foreign issuer)20-F · period to June 30, 2026Regencell Bioscience reported a widening net loss of $11,701,941 for fiscal year 2026 as operating costs rose sharply and the company generated zero revenue.Diluted EPS -$2.37 versus -$0.72.
2. May 22, 2026
   Foreign issuer update 6-K
3. May 19, 2026
   Foreign issuer update 6-K
4. May 19, 2026
   Foreign issuer update 6-K
5. May 8, 2026
   Foreign issuer update 6-K
6. April 17, 2026
   Foreign issuer update 6-K
7. March 30, 2026
   Foreign issuer update 6-K
8. March 30, 2026
   Foreign issuer update 6-K
9. March 30, 2026
   Form F-3ASR filing F-3ASR
10. February 13, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 9, the latest on May 29, 2026. Insider transactions on SEC

Insider trades

What the people running Regencell Bioscience Holdings Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RGC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RGC

What does Regencell Bioscience Holdings Ltd do?

Regencell Bioscience Holdings Ltd is a company in the Health care sector, listed on NASDAQ as RGC. Its shares trade on NASDAQ under the ticker RGC.

What is Regencell Bioscience Holdings Ltd's net worth?

Regencell Bioscience Holdings Ltd has a market value (market cap) of $2.8B at the latest share price, and shareholders' equity of $13.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Regencell Bioscience Holdings Ltd profitable?

No. In fiscal 2026 it reported a net loss of $11.7M.

When did Regencell Bioscience Holdings Ltd last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on October 7, 2026. It covers the period to June 30, 2026.

When is Regencell Bioscience Holdings Ltd's next earnings report?

Regencell Bioscience Holdings Ltd's next report is expected around September 28, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare RGC with

Compare RGC with any company

Follow RGC

Get an email when Regencell Bioscience Holdings Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow RGC

Free, no password. An email when RGC files with the SEC.

Where the numbers come from

Financial figures are the values Regencell Bioscience Holdings Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.